Phase 3 ROSELLA (GOG-3073, ENGOT-ov72) Trial of Relacorilant + Nab-paclitaxel vs Nab-paclitaxel in Platinum-resistant Ovarian Cancer: Primary Results and Outcomes in Older Patients

Olawaiye et al. • 2025 • IGCS

Read more

ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + Nab-Paclitaxel in the Subgroup of Patients With Platinum-Resistant Ovarian Cancer (PROC) Previously Exposed to a PARP Inhibitor

Lorusso et al. • 2025 • ESMO

Read more

Phase 3 Results of Relacorilant + Nab-Paclitaxel v Nab-Paclitaxel In Platinum-Resistant Ovarian Cancer (ROSELLA): Secondary Endpoints

Lorusso et al. • 2025 • ESMO Gyn

Read more

ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer

A. Olawaiye et al. • 2025 •

Read more

Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Colombo et al. • 2024 • SGO 2024 Congress

Read more

ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Platinum-Resistant Ovarian Cancer

Lorusso et al. • 2023 • IGCS 2023 Congress

Read more

ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer

Lorusso et al. • 2023 • ESGO 2023 Congress

Read more

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Colombo et al. • 2023 • Journal of Clinical Oncology

Read more

© 2025 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube